Loading field map
Health economics is the branch of economics concerned with the production, distribution, and consumption of health and healthcare. It applies the tools of economic analysis—incentives, scarcity, choice, efficiency, equity—to a domain where markets often fail, information is deeply asymmetric, and the object of value (health itself) is not a standard commodity. The field does not simply study the healthcare sector as a business; it studies how societies allocate resources to improve health, why those allocations are frequently suboptimal, and how alternative arrangements might do better.
The foundational puzzle of health economics is that health and healthcare violate nearly every assumption of a textbook competitive market. A normal good is one whose consumption increases with income and whose price is determined by supply and demand. Healthcare is different in several fundamental ways.
First, demand for healthcare is unpredictable and often urgent. People do not shop for heart attacks or cancer diagnoses the way they shop for groceries. This creates a role for insurance, which in turn introduces the problem of moral hazard: once insured, people may consume more care than they would if they paid full price, and providers may supply more care than is medically necessary.
Second, information is radically asymmetric. The patient knows their symptoms but not the appropriate treatment; the physician knows the treatment but also has financial incentives that may conflict with the patient's interest. This is the principal–agent problem, and it is central to health economics. The physician acts as an agent for the patient, but the agent's objectives are not perfectly aligned with the principal's.
Third, health itself is a peculiar good. It is a form of human capital—an asset that depreciates with age and can be augmented by medical care, diet, exercise, and other investments. But unlike physical capital, health is also an end in itself. People value being healthy not only because it allows them to work and earn, but because it is intrinsically desirable. This dual nature—health as both investment and consumption—was formalized in the most influential theoretical framework in the field.
In 1972, economist Michael Grossman published a model that remains the theoretical backbone of health economics. In the Grossman model, individuals are born with a stock of health capital that depreciates over time. They can invest in this stock through medical care, diet, exercise, and other health-producing activities. The model treats health as both a consumption good (people derive utility from being healthy) and an investment good (healthier people have more time available for work and leisure).
The model's key insight is that the demand for healthcare is a derived demand. People do not want medical care for its own sake; they want the health that medical care produces. This means that the demand for healthcare depends on the productivity of medical care in producing health, the rate at which health depreciates, the opportunity cost of time spent being sick, and the individual's wage rate. The model predicts that people with higher wages will demand more health (because the opportunity cost of sick time is higher) and will be more efficient producers of health (because they have better information and resources).
The Grossman model has been enormously influential, but it has important limits. It assumes a high degree of individual rationality and foresight, which real patients often lack. It treats health as a single stock, whereas actual health is multidimensional. And it says little about the supply side—the behavior of physicians, hospitals, and insurers—which is where many of the field's most important empirical questions lie.
If the Grossman model explains the demand for health, the supply side of health economics is concerned with how providers respond to incentives. The central question is: what determines the quantity and quality of medical care that physicians and hospitals deliver?
The most contentious concept in this area is supplier-induced demand. The idea is that physicians, because they have more information than patients, can influence the demand for their own services. A fee-for-service payment system, which pays physicians per procedure, creates an incentive to recommend more procedures than a fully informed patient would choose. The concept is empirically difficult to test because one cannot easily distinguish induced demand from appropriate care for sicker patients. But the basic insight—that providers respond to financial incentives—is well established. Studies have shown that physicians who own imaging equipment order more imaging tests, and that physicians in fee-for-service systems perform more surgeries than those in salaried systems.
Payment systems are therefore a central object of study. The major payment models are fee-for-service (payment per procedure), capitation (payment per patient per period, regardless of services used), and bundled or prospective payment (payment per episode of care or per diagnosis). Each creates different incentives. Fee-for-service rewards volume; capitation rewards efficiency but risks under-provision; bundled payment rewards coordination but risks stinting on necessary care. Health economists study how these payment models affect utilization, quality, and cost, and how they can be designed to align provider incentives with patient welfare.
Hospitals add another layer of complexity. They are multi-product firms producing a wide range of services, often with significant fixed costs and economies of scale. They face competition from other hospitals, but that competition is mediated by insurers, regulators, and the fact that patients rarely choose hospitals on price. The structure of hospital markets—whether they are concentrated or competitive, for-profit or non-profit—has been a major area of empirical research. The evidence suggests that non-profit and for-profit hospitals behave differently in some respects but similarly in others, and that hospital competition can improve quality but also lead to duplication of expensive technology.
Health insurance is the mechanism by which individuals pool the financial risk of illness. The economics of insurance is built on the distinction between risk aversion and risk pooling. If people are risk-averse—if they prefer a certain small loss to a possible large loss—they will be willing to pay more than the expected value of their medical costs to avoid the risk of catastrophic expense. This creates the possibility of a welfare-improving insurance market.
But insurance markets face two classic problems. The first is adverse selection: people who know they are likely to need medical care are more likely to buy insurance, which raises premiums, which drives out healthier people, which raises premiums further. This "death spiral" can cause insurance markets to unravel entirely. The second is moral hazard: once insured, people face lower out-of-pocket prices for care, so they consume more care than they would if they bore the full cost.
Health economists have studied these problems extensively. The RAND Health Insurance Experiment, conducted in the 1970s, remains the most influential empirical study of moral hazard. It randomly assigned families to insurance plans with different levels of cost-sharing (from free care to 95% coinsurance) and found that higher cost-sharing reduced healthcare utilization without, on average, harming health. The experiment's findings have shaped the design of insurance plans ever since, particularly the use of deductibles and copayments to reduce moral hazard.
Adverse selection is harder to study experimentally, but its effects are well documented. Insurance markets that do not adjust premiums for risk—or that are required to accept all applicants—tend to attract sicker enrollees. This is why many health systems use mandatory insurance, risk adjustment (paying insurers more for sicker enrollees), or single-payer arrangements to mitigate adverse selection.
Health economics is not only about efficiency; it is also about equity. The field asks not just whether resources are used well, but whether they are distributed fairly. This involves two distinct questions. The first is equity in health outcomes: do different groups—by income, race, geography, or gender—have different levels of health? The second is equity in healthcare access and financing: do people with equal needs receive equal care, and do people with equal ability to pay contribute equally to the cost of care?
The evidence on health inequities is robust. Higher income is associated with better health at every level of the income distribution, a relationship that holds across countries and over time. The causes are complex: income affects health through material resources (better housing, food, medical care), through psychosocial stress, and through behaviors that differ by socioeconomic status. Health economists have also documented substantial geographic variation in healthcare spending and utilization that cannot be explained by differences in illness—the Dartmouth Atlas studies in the United States showed that Medicare spending per beneficiary varies two-fold across regions with no corresponding difference in health outcomes. This variation is often attributed to differences in physician practice styles and the supply of medical resources, rather than to patient needs.
The financing of healthcare raises separate equity questions. Systems funded by general taxation (like the UK's National Health Service) tend to be progressive—the rich pay more than the poor relative to their income. Systems funded by private insurance premiums tend to be regressive—the poor pay a larger share of their income for the same coverage. Health economists study how different financing arrangements affect both the distribution of the financial burden and the distribution of access to care.
Health economics emerged as a distinct subfield in the 1960s and 1970s, driven by the rapid growth of healthcare spending in developed countries and the expansion of public health insurance programs. The field's early years were dominated by the Grossman model and by empirical studies of the demand for medical care. The RAND Health Insurance Experiment, which began in the early 1970s and published its main results in the 1980s, established the field's empirical credibility and its signature method: randomized controlled trials of health policy.
The 1980s and 1990s saw the field expand into the study of provider behavior, hospital competition, and the economics of regulation. The rise of managed care in the United States—health maintenance organizations and other arrangements that sought to control costs by changing provider incentives—provided a natural experiment for studying how payment systems affect behavior. The 2000s brought increased attention to the economics of health behaviors (smoking, obesity, addiction) and to the role of behavioral economics in health decisions. More recently, the field has engaged with the economics of health technology assessment, the value of medical innovation, and the design of health systems in low- and middle-income countries.
Throughout its history, health economics has been methodologically pluralistic. It uses microeconomic theory, econometrics, randomized trials, quasi-experimental methods (such as difference-in-differences and regression discontinuity), and increasingly, machine learning and big data. It is a field defined more by its subject matter than by a single method or theoretical commitment.
Contemporary health economics is organized around several enduring questions rather than a single paradigm. The first is cost containment: how can societies control the growth of healthcare spending without sacrificing health outcomes? This question has become more urgent as healthcare consumes an increasing share of GDP in most developed countries. The second is value: how can we measure the health benefits of medical interventions and ensure that resources are directed toward those with the greatest benefit per dollar? This has led to the growth of cost-effectiveness analysis and the use of quality-adjusted life years (QALYs) as a common metric for comparing interventions.
The third question is system design: what mix of public and private financing, regulation, and competition produces the best outcomes? The comparative study of health systems—the UK's single-payer system, Germany's social insurance model, the United States' mixed private–public system, Singapore's mandatory savings accounts—is a major area of research. The evidence does not support a single best system; each has strengths and weaknesses, and the optimal design depends on a country's values, history, and institutional capacity.
The fourth question is behavioral: why do people make health decisions that seem contrary to their own interests, and how can policy improve those decisions? This draws on behavioral economics, which has shown that people are present-biased (they discount future health risks), loss-averse, and influenced by default options. Policies such as cigarette taxes, calorie labeling, and opt-out organ donation are informed by this research.
The fifth question is global: how can health be improved in low- and middle-income countries, where the burden of disease is highest and resources are scarcest? This subfield, sometimes called global health economics, studies the cost-effectiveness of interventions like vaccination, insecticide-treated bed nets, and antiretroviral therapy, as well as the design of health financing systems in poor countries.
Health economics has been criticized from several directions. Some critics argue that the field's focus on efficiency and cost-effectiveness neglects the intrinsic value of health and the importance of equity. The QALY, for example, values a year of life equally regardless of who lives it, but it also implicitly values a year of life for a young person more than for an old person (because the young person has more future years). This has led to accusations of age discrimination. Others argue that the field's reliance on rational-choice models underestimates the complexity of medical decision-making and the role of trust, compassion, and professional ethics in healthcare.
A more fundamental criticism is that health economics treats health as if it were primarily a matter of individual choice and market incentives, when in fact the social determinants of health—income inequality, housing, education, environmental conditions—may matter more than medical care itself. This critique has force, but it is not entirely fair: health economists have been central in documenting the social gradient in health and in studying how non-medical policies affect health outcomes.
The field's limits are also practical. Healthcare systems are complex, and the effects of policy changes are often difficult to predict. The evidence base is strong on some questions (the effect of cost-sharing on utilization) and weak on others (the effect of hospital competition on quality). Health economists are increasingly aware of these limits and have become more cautious in their claims, emphasizing the conditions under which their findings hold and the uncertainty that remains.
Despite these criticisms, health economics has made durable contributions to how societies think about health. It has provided the conceptual framework for understanding why healthcare markets fail and why government intervention is often necessary. It has developed the tools—cost-effectiveness analysis, risk adjustment, payment design—that are used in health systems around the world. It has generated a large body of empirical evidence on what works and what does not, from the effects of insurance on health to the consequences of different payment models.
The field's central insight is simple but profound: health is scarce, and choices about how to produce and distribute it are unavoidable. Health economics does not tell societies what those choices should be, but it provides the analytical tools to understand their consequences. In a world where healthcare consumes a growing share of national income and where health inequities persist within and between countries, that analytical capacity is more valuable than ever.